The Chosun Ilbo on MSN

Vanoglipel emerges as dual MASH-diabetes treatment with combination potential

Following the success of obesity treatments, global pharmaceutical and biotech industries are increasingly focusing on the ...
The American Journal of Managed Care

Real-World Data Show MASH Progresses Faster Than Trials Suggest

Progression from F3 to cirrhosis occurred in roughly one year, contrasting STELLAR’s 13% over four years and suggesting trials may underrepresent real-world risk. Among compensated cirrhosis, 29.7% ...
Medical Xpress

MASH discovery redefines subtypes with distinct risks: Findings could shape future of fatty liver disease treatment

Metabolic dysfunction-associated steatotic liver disease (MASLD), formerly referred to as nonalcoholic fatty liver disease (NAFLD), impacts roughly 30% of the global adult population. The disease ...
Healthline

10 Symptoms That Could Actually Be a Sign of MASH

Metabolic dysfunction-associated steatohepatitis (MASH) is a “silent disease” that often has no early symptoms, yet can progress to cirrhosis or liver failure. Possible MASH symptoms include ...
Yahoo Finance

Novo Nordisk A/S: Wegovy® approved in the US for the treatment of MASH

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...